Table 1 Profiles of concomitant medications and costs (2008 CA$)
From: Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Health state | Medications | Proportion | Daily dose | Drug costs per 12 weeks | Total costs of health state |
|---|---|---|---|---|---|
Remission | None | - | - | - | $0.00 |
Active UC | |||||
Responsive | 5-ASA | 0.9 | 4 g | $348.83 | $698.44 |
mesalamine enema | 1.0 | 4 g | $384.50 | ||
Nonresponsive | 5-ASA | 0.9 | 4 g | $348.83 | $786.55 |
mesalamine enema | 1.0 | 4 g | $384.50 | ||
azathiopirne/6 MP* | 0.4 | 150/75 mg | $222.76 |